PHAXIAM Therapeutics S.A.
PHXM
Rankning i aktier
#39380
PHAXIAM Therapeutics S.A. is a biopharmaceutical firm dedicated to creating... PHAXIAM Therapeutics S.A. is a biopharmaceutical firm dedicated to creating therapies for drug-resistant bacterial infections, operating in both France and the U.S. The company's pipeline includes eryaspase, currently undergoing Phase 3 clinical trials for advanced pancreatic cancer and Phase 2 studies for treating triple-negative breast cancer and acute lymphoblastic leukemia after initial treatments. Additionally, PHAXIAM is advancing a range of phage therapies designed to combat hazardous, drug-resistant bacteria. These pathogens, such as Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa, are responsible for over two-thirds of all resistant infections acquired in hospital settings. Established in 2004, the company was previously known as ERYTECH Pharma S.A. before adopting the name PHAXIAM Therapeutics S.A. in June 2023. Its corporate headquarters are located in Lyon, France.
Aktiekurs
$0.11725176
Senast synkroniserad: 2025-07-14
Marknadsvärde
$481.50K
Förändring (1 dag)
-0.20%
Förändring (1 år)
3.89%
Land
FR
Handel PHAXIAM Therapeutics S.A. (PHXM)
Kategori
Healthcare
Historik för aktiesplit för PHAXIAM Therapeutics S.A. (PHXM)
Aktien PHAXIAM Therapeutics S.A. (symbol: PHXM) har genomgått totalt 0 aktiesplitar.
Den senaste spliten skedde den Oct 21, 2026.
En PHXM-aktie köpt före Oct 21, 2026 motsvarar nu 0 PHXM-aktier.
Den senaste spliten skedde den Oct 21, 2026.
En PHXM-aktie köpt före Oct 21, 2026 motsvarar nu 0 PHXM-aktier.
Lista över aktiesplitar
| År | Split | Multipel | Kumulativ multipel |
|---|---|---|---|
| Inte tillräckligt med data för de angivna datumen. | |||
Aktiesplitar för liknande företag eller konkurrenter
| Företag | Antal aktiesplitar | Kumulativ multipel | Land |
|---|---|---|---|
| 1 | x2 |
US
|
|
| 0 | - |
US
|
|
| 1 | x3 |
AU
|
|
| 0 | - |
NL
|
|
| 0 | - |
CH
|
